Fulgent Genetics Awarded Contract by the U.S. Department of Veterans Affairs to Provide Hereditary Cancer, Pharmacogenetic and Other Genetic Testing to Veterans¹
Fulgent Genetics, Inc. (FLGT)
Last fulgent genetics, inc. earnings: 3/10 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.fulgentgenetics.com
Company Research
Source: Business Wire
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced it has been awarded a five-year contract by the U.S. Department of Veterans Affairs (VA) to provide hereditary cancer, pharmacogenetic and other genetic testing to Veterans.A leader in clinical molecular diagnostic testing, Fulgent has been periodically providing genetic testing services to the members of the VA since 2017. These have included both clinical and research-based services. This new award enables Fulgent to provide hereditary cancer tests to individuals with cancer or a family history of certain cancers, enhancing the services available to the VA community. In addition, the contract includes pharmacogenetic testing. Pharmacogenetics uses genomic information to determine how patients will respond to certain medications--an important c
Show less
Read more
Impact Snapshot
Event Time:
FLGT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FLGT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FLGT alerts
High impacting Fulgent Genetics, Inc. news events
Weekly update
A roundup of the hottest topics
FLGT
News
- Oncology Specimen Provider Reference Medicine Announces Launch of Characterized Specimens, Enabling Increased Speed and Efficiency for Assay DevelopersPR Web
- Fulgent Genetics, Inc. (NASDAQ: FLGT) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- Fulgent Genetics, Inc. (NASDAQ: FLGT) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Fulgent Genetics, Inc. (NASDAQ: FLGT) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Fulgent Genetics, Inc. (NASDAQ: FLGT) had its price target lowered by analysts at Piper Sandler from $26.00 to $22.00. They now have a "neutral" rating on the stock.MarketBeat
FLGT
Earnings
- 11/8/24 - Beat
FLGT
Sec Filings
- 11/8/24 - Form 10-Q
- 11/8/24 - Form 8-K
- 11/5/24 - Form SC
- FLGT's page on the SEC website